Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis

Abstract

Background: Immune checkpoint inhibitors (ICIs) are becoming widely used for novel cancer treatments. Immune-related adverse events, including cardiac toxicity, are frequently observed following immune checkpoint inhibitor (ICI) use. However, little is known regarding the association between ICIs initiation and hypertension in cancer patients. Methods: A systematic literature search was performed using PubMed, EMBASE, Cochrane Library, and Web of Science Core Collection. The risk of hypertension associated with ICI initiation in randomized controlled trials (RCTs) was evaluated. Hypertension was categorized according to the Common Terminology Criteria for Adverse Events. The odds ratios of grades I to V and grades III to V hypertension were calculated using a random-effects meta-analysis. Results: Thirty-two RCTs (n=19 810 cancer patients) were included. At a median follow-up of 36 months, the median overall survival was 15 months in the ICI group. ICI initiation was not significantly associated with hypertension (grades I–V: odds ratio, 1.12 [95% CI, 0.96–1.30]; grades III–V: odds ratio, 0.95 [95% CI, 0.78–1.16]). Additionally, no significant differences in hypertension risk were evident in ICI combination therapies with various drugs, including anti-VEGF (vascular endothelial growth factor) agents. In a subgroup analysis based on clinical setting (placebo RCT versus nonplacebo RCT), there were discrepancies between the results obtained with different methodologies, with patients in the nonplacebo RCTs having higher grades I–V hypertension (I 2 =88.6%, P for heterogeneity=0.003). Conclusions: ICI initiation was not associated with short-term risk of hypertension in cancer patients, and the association was similar regardless of concomitant treatment with other anticancer drugs.

Comprehensive pan-cancer analysis and the regulatory mechanism of AURKA, a gene associated with prognosis of ferroptosis of adrenal cortical carcinoma in the tumor micro-environment

“…The discovery of immunological checkpoints opens up new avenues for tumor therapy. Immune checkpoint inhibitors have been employed in treating many tumors recently, and their effectiveness and safety have been objectively validated ( Cai et al, 2022 ; Minegishi et al, 2022 ). In addition, we discovered an intriguing phenomenon.…”

Onconephrology 2022: An Update

“…Recently a systematic review and meta-analysis was performed by Minegishi et al to look at the incidence of HTN from immune checkpoint inhibitors. Thirty-two randomized controlled trials with around 19,000 patients included in the meta-analysis did not show any increased association with short term risk of HTN in patients with cancer and the association was similar regardless of concurrent treatment with other anticancer medications 68 .…”

Impact of Hypertension in Cancer Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy

“…Myocarditis, arrhythmias, and conduction abnormalities are serious and potentially life-threatening adverse events affecting cancer patients; ICI use has also been reported to increase CVD risk but has proven not to increase the risk of HTN in the short-term. 14 Common risk factors and interrelationships exist between HTN and cancer. Alone or in combination, they may lead to CVD and ultimately to a worsened quality of life and prognosis.…”